NCT00961090View on ClinicalTrials.gov

Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

April 22, 2015

Study Completion Date

April 23, 2015

Conditions
Glioblastoma
Interventions
DRUG

Aminolevulinic Acid

20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery

Trial Locations (1)

15212

Allegheny General Hospital, Pittsburgh

Sponsors
All Listed Sponsors
collaborator

DUSA Pharmaceuticals, Inc.

INDUSTRY

lead

Matthew R Quigley

OTHER